Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study ☆
Titel:
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study ☆
Auteur:
Gianni, L. Huang, C.S. Egle, D. Bermejo, B. Zamagni, C. Thill, M. Anton, A. Zambelli, S. Bianchini, G. Russo, S. Ciruelos, E.M. Greil, R. Semiglazov, V. Colleoni, M. Kelly, C. Mariani, G. Del Mastro, L. Maffeis, I. Valagussa, P. Viale, G.